AzTrials
AzTrials

Traumatic Brain InjuryNCT03698747

Myelin Imaging in Concussed High School Football Players

An observational study of Traumatic Brain Injury, run by Memorial Healthcare System at 1 site in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

Investigate myelin alterations in high school football players with mTBI Read more about this study

Who is it for?
Ages 13 to 18 years, men only
Conditions the study is for
Traumatic Brain Injury
What is being tested?
McDESPOT
Type of treatment
Medical device
How many people
13 participants
Where
1 siteUnited States
Study dates
4 Sep 2018to 12 Aug 2020
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 13 to 18 years
  • Men only
  • Child, Adult

Study population: High school age (9th-12th grade), male, right-handed Diagnosed with concussion or mild traumatic brain injury

Who may be able to join

  • Experimental Group
  • Patient age range: 9th through 12th grade (high school)
  • Male
  • Right-handed
  • Diagnosis of mTBI or concussion during a football game or training
  • No significant co-morbidities
Show all 15Show fewer
  • Able to get an MRI
  • Potential subject must be capable of giving informed consent or assent when applicable
  • Control Group
  • Patient age range: 9th through 12th grade (high school)
  • Male Right-handed
  • Does not play contact sports (football, soccer, lacrosse)
  • No significant co-morbidities
  • Able to get an MRI
  • Potential subject must be capable of giving informed consent or assent when applicable

Who cannot join

  • Unable to tolerate MRI scan

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Memorial Healthcare System

    Hollywood, Florida, 33021

Other trials in United States

About this study

Official title: A Prospective Study of Myelin Imaging Changes in Concussed High School Football Players

Investigate myelin alterations in high school football players with mTBI

Read the detailed description

The lack of highly sensitive clinical neuroimaging and neuropsychiatric markers of subtle changes due to mTBI makes it difficult to characterize injury severity and to predict outcomes. White matter tracts in the brain, both myelinated and non-myelinated, are susceptible to damage from impact-acceleration forces experienced during a TBI,5-7 and there is evidence that significant white matter injury and myelin loss occurs in mTBI. In addition, this damage may be chronic and can negatively affect neural processing speed and cognitive function. Traditional anatomical and function MRI imaging sequences include clinical sequences such as traditional T1 and T2 sequences, fluid-attenuated inversion recovery (FLAIR), three-dimensional (3D) magnetization-prepared rapid gradient echo (MP-RAGE), diffusion-weighted imaging (DWI) and gradient MRI. While a number of advanced imaging techniques, notably magnetization transfer, diffusion tensor and quantitative T1 and T2 imaging (MTI, DTI, qT1 and qT2, respectively), have been used previously to study white matter in neurosurgical diseases, these methods provide only indirect, non-specific information related to myelin content. For example, these modalities can tell when there is swelling that is affecting the movement of water, which may be indicative of a process that would affect myelin, but they cannot give specific information about the amount of myelin surrounding a nerve. An emerging multicomponent relaxometry technique, termed multicomponent driven equilibrium single pulse observation of T1 and T2 (mcDESPOT), provides a voxel-wise estimation ranging from 0 to 1 for myelin content, with higher values providing an indirect marker of greater myelin integrity. Two studies have shown increased myelin after injury in football and ice hockey players.8 DTI, which primarily gives information about the myelin-axon bundle interactions, has shown decreased fractional anisotropy after mTBI,myelin-axon bundle interactions, has shown decreased fractional anisotropy after mTBI, indicating that the myelin that is present is less organized.8 Combining mcDESPOT and DTI findings, it is possible to see a more nuanced picture of the remyelination process after mTBI. In the present program, the investigators propose adding the mcDESPOT sequence to the MRI scanner in accordance with the MRI manufacturer's technical requirements. Although the sequences obtained for mcDESPOT are nearly identical sequences used in clinical practice, the flip-angles are changed so that they cannot be read like a traditional image.

Rather, the data have to be post-processed by a computer in order to be able to derive myelin information. The mcDESPOT sequences are FDA approved, and present no additional risk over traditional clinical MRI sequences. Apolipoprotein E (ApoE) is a class of proteins involved in the metabolism of fats in the body, and is important in Alzheimer's disease and cardiovascular disease. How the body makes this protein is genetically coded in the APoE gene. One form of this gene, APoE allele 4 (APoE4) is found in about 25% of the population, but in 60% of patients with Alzheimer's dementia. Infants with this allele also show decreased myelination at a young age. It is postulated that this defect affects the brain's ability to myelinate and remyelinate, leading to decreased or disorganized myelination, which then leads to an increased risk for development of dementia. This study aims to build upon preliminary data collected by the principal investigator (PI) showing increased but disorganized myelin in collegiate football players, by confirming and reproducing these results in a larger population. This study will also add the component of genetic testing for the APoE4 allele to see if there is a sub-segment of the study population that may be at increased risk for brain injury after mTBI and subsequent findings in the research scans. The mcDESPOT and genetic testing findings will also be correlated with routine neuropsychology concussion assessment results.

Being tested
McDESPOT
Medical subject headings
Brain Injuries, Traumatic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • McDESPOTDevice

    myelin specific MRI sequence (mcDESPOT) added to standard MRI sequence

Study groups in NCT03698747
Study groupRoleWhat they receive
mTBI Study Group with McDESPOT sequenceStudy group (30 subjects) of football players diagnosed with mTBI (scan at diagnosis, 3-month follow-up scan, genetic screening, concussion assessment at both interaction)
Receives: Device: McDESPOT
Control GroupControl group (30 subjects) of age match non-contact sport players (scan, genetic testing, concussion assessment)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Myelin Disruption on MRI brain scan

    Determine whether mTBI in football players leads to increased, but disorganized, myelin compared to non-contact sports players.

    Measured: 3 months

Secondary outcomes (2)
  1. APoE4 allele genetic mutation on blood test

    Explore whether a genetic mutation in the APoE4 allele predisposes football players to decreased or disorganized myelination after mTBI.

    Measured: 3 months

  2. Neuropsychiatric concussion correlation

    Correlate any changes in myelination or of genetics with neuropsychiatric concussion assessment.

    Measured: 3 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Oct 2018
  2. Study start4 Sep 2018
  3. Primary completion12 Aug 2020
  4. Study completion12 Aug 2020

Why it stopped: PI left organization

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
13 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03698747
Sponsor's protocol ID
MTBI
Status last verified
Sep 2020
First submitted
4 Oct 2018
Last updated
25 Sep 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Traumatic Brain Injury, run by Memorial Healthcare System at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 15 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 25 Sep 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: PI left organization). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Myelin Disruption on MRI brain scan (time frame: 3 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Sep 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in